Nicholas Investment Partners’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Nicholas Investment Partners’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-446,674	Closed	-$20M	–	222
2021 Q1	$20M	Buy	446,674 +185,876	+71%	+$8.65M	1.4%	19
2020 Q4	$14.9M	Buy	260,798 +43,815	+20%	+$2.6M	1.15%	28
2020 Q3	$11.1M	Buy	216,983 +169,872	+361%	+$8.32M	1.2%	27
2020 Q2	$2.81M	Sell	47,111 -51,188	-52%	-$2.74M	0.57%	66
2020 Q1	$4.05M	Buy	+98,299	New	+$5.46M	0.79%	42

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nicholas Investment Partners's DCPH Position: Q2 2021 in Review

Nicholas Investment Partners sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2021, closing a stake of 446,674 shares — an estimated $20M sold.

Nicholas Investment Partners first reported a position in DCPH in Q1 2020 and held it in 5 quarters. The position peaked at $20M in Q1 2021. 147 funds tracked by Wall St. Rank hold DCPH as of Q2 2021.

Nicholas Investment Partners reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Nicholas Investment Partners sold 446,674 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $20M.
Nicholas Investment Partners first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Nicholas Investment Partners's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $20M in Q1 2021.
147 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Nicholas Investment Partners's 13F filing for Q2 2021, filed 10 Aug 2021.